MA34512B1 - Formes solides amorphes du chlorhydrate de la 4-[-2-[[5-méthyl-1-(2-naphtalényl)-1h-pyrazol-3-yl]oxy]éthyl]morpholine - Google Patents

Formes solides amorphes du chlorhydrate de la 4-[-2-[[5-méthyl-1-(2-naphtalényl)-1h-pyrazol-3-yl]oxy]éthyl]morpholine

Info

Publication number
MA34512B1
MA34512B1 MA35713A MA35713A MA34512B1 MA 34512 B1 MA34512 B1 MA 34512B1 MA 35713 A MA35713 A MA 35713A MA 35713 A MA35713 A MA 35713A MA 34512 B1 MA34512 B1 MA 34512B1
Authority
MA
Morocco
Prior art keywords
naphthalenyl
pyrazol
ethyl
methyl
solid forms
Prior art date
Application number
MA35713A
Other languages
English (en)
French (fr)
Inventor
Buchholz Jordi Benet
Fernandez Laura Puig
Original Assignee
Esteve Labor Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esteve Labor Dr filed Critical Esteve Labor Dr
Publication of MA34512B1 publication Critical patent/MA34512B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MA35713A 2010-08-09 2011-08-08 Formes solides amorphes du chlorhydrate de la 4-[-2-[[5-méthyl-1-(2-naphtalényl)-1h-pyrazol-3-yl]oxy]éthyl]morpholine MA34512B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10382225A EP2426111A1 (en) 2010-08-09 2010-08-09 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride amorphous solid forms
PCT/EP2011/063583 WO2012019984A1 (en) 2010-08-09 2011-08-08 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride amorphous solid forms

Publications (1)

Publication Number Publication Date
MA34512B1 true MA34512B1 (fr) 2013-09-02

Family

ID=43244877

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35713A MA34512B1 (fr) 2010-08-09 2011-08-08 Formes solides amorphes du chlorhydrate de la 4-[-2-[[5-méthyl-1-(2-naphtalényl)-1h-pyrazol-3-yl]oxy]éthyl]morpholine

Country Status (19)

Country Link
US (1) US9428462B2 (ja)
EP (2) EP2426111A1 (ja)
JP (1) JP5899214B2 (ja)
KR (1) KR20130095751A (ja)
CN (1) CN103052626B (ja)
AR (1) AR082608A1 (ja)
AU (1) AU2011288550A1 (ja)
BR (1) BR112013002651A2 (ja)
CA (1) CA2807855C (ja)
CO (1) CO6670586A2 (ja)
ES (1) ES2543429T3 (ja)
HK (1) HK1186468A1 (ja)
MA (1) MA34512B1 (ja)
MX (1) MX341711B (ja)
PT (1) PT2603495E (ja)
RU (1) RU2013110313A (ja)
SG (1) SG187745A1 (ja)
TW (1) TW201219387A (ja)
WO (1) WO2012019984A1 (ja)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2116539A1 (en) 2008-04-25 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof
EP2353591A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof
EP2353598A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for use in the prevention and/or treatment of postoperative pain
EP2388005A1 (en) 2010-05-21 2011-11-23 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy
EP2415471A1 (en) 2010-08-03 2012-02-08 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in opioid-induced hyperalgesia
EP2524694A1 (en) 2011-05-19 2012-11-21 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in diabetes type-2 associated pain
EP2792352A1 (en) 2013-04-16 2014-10-22 Laboratorios Del. Dr. Esteve, S.A. Alpha-2 adrenoreceptor and sigma receptor ligand combinations
JP2016540771A (ja) 2013-12-17 2016-12-28 ラボラトリオス・デル・ドクトル・エステベ・ソシエダッド・アノニマ セロトニン−ノルアドレナリン再取り込み阻害薬（ｓｎｒｉ）およびシグマ受容体リガンドの組み合わせ
EP3082790A1 (en) 2013-12-17 2016-10-26 Laboratorios Del. Dr. Esteve, S.A. Gabapentinoids and sigma receptor ligands combinations

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04364129A (ja) * 1990-10-26 1992-12-16 Asahi Chem Ind Co Ltd ６−置換アルコキシキノキサリン誘導体含有医薬組成物およびその製造法
SE508669C2 (sv) 1996-04-26 1998-10-26 Astra Ab Nytt förfarande
SI1781618T1 (sl) * 2004-08-27 2013-01-31 Laboratorios Del Dr. Esteve, S.A. Inhibitorji sigma receptorja
JP5139061B2 (ja) 2004-08-27 2013-02-06 ラボラトリオス デル ドクトール エステベ エセ．ア． シグマ受容体阻害剤
EP1634872A1 (en) * 2004-08-27 2006-03-15 Laboratorios Del Dr. Esteve, S.A. Pyrazole derivatives as sigma receptor inhibitors
JPWO2009038112A1 (ja) 2007-09-21 2011-01-06 塩野義製薬株式会社 Ｎｐｙｙ５受容体拮抗剤を含有する固形製剤
EP2116539A1 (en) * 2008-04-25 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof
EP2113501A1 (en) * 2008-04-25 2009-11-04 Laboratorios Del. Dr. Esteve, S.A. 5-Methyl-1-(naphthalen-2-YL)-1H-Pyrazoles useful as sigma receptor inhibitors
EP2292236A1 (en) * 2009-08-14 2011-03-09 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for the prevention or treatment of pain induced by chemotherapy
EP2335688A1 (en) * 2009-11-25 2011-06-22 Laboratorios Del. Dr. Esteve, S.A. Pharmaceutical compositions comprising sigma receptor ligands
RS55099B1 (sr) * 2009-11-25 2016-12-30 Esteve Labor Dr Hirohloridna so 4-[2-[[5-metil-1-(2-naftalenil)-1h-pirazol-3-il]oksi]etil]morfolina
EP2361904A1 (en) 2010-02-04 2011-08-31 Laboratorios Del. Dr. Esteve, S.A. 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride and crystalline forms thereof
EP2426112A1 (en) 2010-08-09 2012-03-07 Laboratorios Del. Dr. Esteve, S.A. 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride polymorphs and solvates
PT2531177T (pt) * 2010-02-04 2016-08-17 Esteve Labor Dr Polimorfos e solvatos de cloridrato de 4-[-2-[[5-metil-1-(2-naftalenil)-1h-pirazol-3-il]oxi]etil]morfolina
EP2353598A1 (en) * 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for use in the prevention and/or treatment of postoperative pain
EP2388005A1 (en) * 2010-05-21 2011-11-23 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy
EP2415471A1 (en) * 2010-08-03 2012-02-08 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in opioid-induced hyperalgesia
EP2460519A1 (en) * 2010-12-03 2012-06-06 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in bone cancer pain

Also Published As

Publication number Publication date
JP5899214B2 (ja) 2016-04-06
SG187745A1 (en) 2013-03-28
ES2543429T3 (es) 2015-08-19
WO2012019984A1 (en) 2012-02-16
HK1186468A1 (en) 2014-03-14
CN103052626A (zh) 2013-04-17
US9428462B2 (en) 2016-08-30
CA2807855C (en) 2018-10-23
MX341711B (es) 2016-08-31
RU2013110313A (ru) 2014-09-20
CA2807855A1 (en) 2012-02-16
CN103052626B (zh) 2017-06-06
EP2603495B1 (en) 2015-05-06
TW201219387A (en) 2012-05-16
AU2011288550A1 (en) 2013-02-21
MX2013001559A (es) 2013-03-07
EP2603495A1 (en) 2013-06-19
KR20130095751A (ko) 2013-08-28
US20130150575A1 (en) 2013-06-13
CO6670586A2 (es) 2013-05-15
PT2603495E (pt) 2015-08-28
JP2013533298A (ja) 2013-08-22
AR082608A1 (es) 2012-12-19
BR112013002651A2 (pt) 2016-05-31
EP2426111A1 (en) 2012-03-07

Similar Documents

Publication Publication Date Title
MA34512B1 (fr) Formes solides amorphes du chlorhydrate de la 4-[-2-[[5-méthyl-1-(2-naphtalényl)-1h-pyrazol-3-yl]oxy]éthyl]morpholine
AU2009270856A8 (en) Inhibitors of Bruton's tyrosine kinase for the treatment of solid tumors
UA108087C2 (uk) Тверді форми n-(4-(7-азабіцикло[2.2.1]гептан-7-іл)-2-(трифторметил)феніл)-4-оксо-5-(трифторметил)-1,4-дигідрохінолін-3-карбоксаміду
TW201713640A (en) Bruton's tyrosine kinase inhibitors
EA201590748A1 (ru) Противовирусные соединения против rsv
EA201590330A1 (ru) Соли и твердые формы (s)-3-(4-((4-(морфолинометил)бензил)окси)-1-оксоизоиндолин-2-ил)пиперидин-2,6-диона и включающие их композиции и способы их применения
MA38071B1 (fr) Formes cristallines d'un inhibiteur de facteur xia
MX2012004258A (es) Inhibidores de la tirosina quinasa de bruton.
DE602007007985D1 (de) Als inhibitoren von proteinkinasen geeignete aminopyrimidine
EA201001017A1 (ru) 3h-[1,2,3]триазоло[4,5-d]пиримидиновые соединения, их применение в качестве ингибиторов киназы mtor и киназы pi3 и их синтезы
MY150547A (en) Protein kinase inhibitors
AU2012243329A8 (en) 5-substituted iminothiazines and their mono-and dioxides as BACE inhibitors,compositions,and their use
MX2012003555A (es) Composicion farmaceutica que comprende acido graso omega-3 y derivado hidroxi de una estatina y metodos para usar la misma.
PT2297120E (pt) Derivados de aminodi-hidrotiazina como inibidores da bace para o tratamento da doença de alzheimer
MX2014000518A (es) Inhibidores de la tirosina quinasa de bruton.
EA201001680A1 (ru) Соединения бензолсульфонамидтиазола и оксазола
WO2008011560A3 (en) Benzothiophene inhibitors of rho kinase
ATE447559T1 (de) 4-(phenylamino)-6-oxo-1,6-dihydropyridazine-3- carboxamid derivate als mek inhibitoren zur behandlung von hyperproliferativen erkrankungen
ATE497961T1 (de) Als proteinkinaseinhibitoren geeignete verbindungen
MA34047B1 (fr) Polymorphes et solvates de chlorhydrate de 4-[-2-[[5-méthyl-1-(2-naphtalényl)-1h-pyrazol-3-yl]oxy]éthyl]morpholine
EA201390766A1 (ru) БЕНЗОКСАЗЕПИНЫ КАК ИНГИБИТОРЫ PI3K/mTOR И СПОСОБЫ ИХ ИСПОЛЬЗОВАНИЯ И ПОЛУЧЕНИЯ
EA201070395A1 (ru) Ингибиторы polo-подобных киназ
EA201100334A1 (ru) Бициклические производные триазола для лечения опухолей
EA201170680A1 (ru) Ингибиторы акт и p70 s6-киназы
EA201001524A1 (ru) Ингибиторы дезацетилазы в, основанные на гидроксамате